Safety The Food and Drug Administration (FDA) has updated the Warnings and Precautions sections of prescribing information for the bisphosphonate agents, including risedronate sodium tablets and combinations with calcium (Actonel/Atelvia), alendronate and combinations with vitamin D (Binosto/Fosamax), ibandronate (Boniva), etidronate (Didronel) and the RANK-ligand inhibitor denosumab (Prolia/Xgeva).1 This information relates to an increased risk for…
Search results for: Biologics
Pediatric to Adult Care Transition Challenging for Patients with JIA
Dr. Sheffield is an adult rheumatologist who received the following referral request from a family doctor: “Please see this 22-year-old male with a history of juvenile arthritis for ongoing care. I have only seen him once, and have no previous medical records.” Dr. Sheffield meets with Paul, who reports that he has had arthritis since…
The ACR, Rheumatologists Advance Issues Through Advocacy
Rheumatologists and rheumatology health professionals make a difference every day in the lives of patients. And through the work of many devoted members, the College takes that commitment beyond the care setting and into the policy arena to Advance Rheumatology! on Capitol Hill and in state capitols across the country. I want to take a…
First Biosimilar Drugs Approved in U.S., Canada
The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…
2014 ACR/ARHP Annual Meeting: Macrophage Activation Syndrome
The pathogenesis of and new classification criteria for MAS
2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA
Review of clinical research on methotrexate therapy, effect on patients’ functionality, tolerability, adverse events
Medication Non-Adherence by Rheumatology Patients & What Rheumatologists Can Do
Lack of efficacy, poor DAS scores may be misinterpreted as a drug failure
New Therapeutics for Osteoarthritis May Be in Sight
Overview of OA pathogenesis, recent discoveries suggest new treatment strategies are possible
The ACR Recommends Cautious Approach as Biosimilars Enter U.S. Market
With the U.S. FDA’s first approval of a biosimilar drug earlier this month, rheumatologists stress the need to ensure safety, efficacy of such drugs in treating rheumatic diseases
Patient’s Journey with Rheumatoid Arthritis Redefines ‘Treat to Target’
Rheumatologist Richard Brasington, MD, says patient John Reigstad’s active participation in treatment decisions shows how much improving quality of life matters
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 77
- Next Page »